Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. - Wikidata - awgldk - TriplyDB

Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.

Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.

http://www.wikidata.org/entity/Q46924646

about

Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization Clinical Trials in Retinal Dystrophies Microvascular complications and diabetic retinopathy: recent advances and future implications Immunology of AAV-Mediated Gene Transfer in the Eye Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularization Hypoxia-induced upregulation of pigment epithelium-derived factor by retinal glial (Müller) cells Expression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurity Optimizing atoh1-induced vestibular hair cell regeneration.A review of gene delivery and stem cell based therapies for regenerating inner ear hair cells Pigment epithelium-derived factor gene polymorphisms in exudative age-related degeneration in a chinese cohort.Macrophages inhibit neovascularization in a murine model of age-related macular degeneration A review of drug options in age-related macular degeneration therapy and potential new agents.Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.Prospects for nanomedicine in treating age-related macular degeneration.Current and emerging therapies for the treatment of age-related macular degeneration An empty E1, E3, E4 adenovirus vector protects photoreceptors from light-induced degeneration Adenovirus vectors targeting distinct cell types in the retina.A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE.Genetics of age-related macular degeneration: application to drug design Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications The potential of nanomedicine therapies to treat neovascular disease in the retina.Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration.Vector platforms for gene therapy of inherited retinopathies.Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration.Gene transfer for neovascular age-related macular degeneration.Adenovector-mediated gene delivery to human umbilical cord mesenchymal stromal cells induces inner ear cell phenotype.Extra cellular matrix derived metabolite regulates angiogenesis by FasL mediated apoptosis MicroRNA-410 reduces the expression of vascular endothelial growth factor and inhibits oxygen-induced retinal neovascularization.Gene therapy for ocular diseases Future therapies of wet age-related macular degeneration.Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy.Development of gene therapy for treatment of age-related macular degeneration.Republished review: Gene therapy for ocular diseases.Association of PEDF polymorphisms with age-related macular degeneration and polypoidal choroidal vasculopathy: a systematic review and meta-analysis.Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage.Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes

P2860

Q24594147-A0FDA392-9246-475F-89CA-5BA34152F179 Q24630406-D4FBDE99-7895-4DEE-B6AC-7774165B486F Q26767086-6B22BAEB-2091-44C4-B31F-C06B16D9EAC5 Q26822476-3C42052D-17E7-4E60-B5A7-97794BEC840D Q27023474-575F0EE9-A9D2-4622-837F-BE5B46498733 Q28487648-4B11C0FE-5E49-485B-B6A5-DD1B3D6439D5 Q28572018-7A05F0CC-00DF-4591-8BD0-B45ED51F2A27 Q28583644-E93F6EF0-8472-49CD-BFA0-06F87262D94A Q30364993-7FCC34B1-122F-4655-BC2D-A745DF3033A0 Q30436837-3B09373A-43EC-474C-B2A4-9589B7171649 Q30993369-A13E56B0-354A-4A62-BFEB-F152EBECB69F Q33253660-FF525A20-B361-4CFF-B273-FEA784C7D810 Q33263803-25C62626-68C8-4874-97D3-022FBAF7A311 Q33397385-D028E3C1-8B2F-4B2A-9DCE-B440E5684798 Q33424022-E3B32468-E238-48DB-B694-F366AF931053 Q33492370-D26AED87-9B60-486F-A288-E6AACA0DEB86 Q33574612-BC7D27D4-9AA8-4BB0-86F2-A2FA87176C10 Q33845053-ECDC312D-F329-4953-93C1-296314890A4A Q33892696-D4356260-9413-4F13-8E49-87F87F61B647 Q33992484-759E967B-A2A8-4BE4-9CD4-3C289C3904EE Q34069606-CBB17A24-1123-4D99-85C5-3A8B20250C7C Q34103580-CAD4961D-FF6C-48DA-8B3A-40E37F3F1EC6 Q34215308-431CD0EF-BBEE-4311-9362-E8AD4D0DA7BB Q34220590-1493A7D0-F683-4F0C-A8BD-6A89399A46AF Q34449898-21CC8432-2BB1-4204-9D09-BB04C276B769 Q34561531-27335968-03C1-4ED2-B750-C5DFC5537F8A Q34662323-A8B00D2A-45D1-4092-A068-828D8023950E Q34843778-0EA7E10C-879B-40BA-9D51-4496942F4667 Q34983847-A6738AD3-D309-4397-9A7E-07137C0F42D0 Q35063753-D8FD12CD-3CC1-4903-8AD3-0F08ABD449C7 Q35159008-5169D44C-E1B2-400A-9A37-A904B9D8A5FA Q35160142-3768BE8A-6FEC-459D-B642-08FE8B9F0A31 Q35162495-2D855A3D-3403-4A9E-AD11-1BB64AFE0751 Q35188790-90772172-1F54-407B-9828-46B179AE09DA Q35192906-CFCB1DD5-E34E-4169-AFE9-E4C42D4031A5 Q35210756-B9D1A97B-2822-4292-BF26-818EC3F60F76 Q35227249-7F8183D1-6F53-4385-AE6B-2B1BA070BE17 Q35594134-DC96456E-0844-44CF-B5B4-EB62B78AD2B6 Q35662043-B8B61FC6-A372-4E96-ABA6-3B390A73A443 Q35762984-9AB1CBDA-FDE2-4C15-B1D9-C8CB50084595

P2860

Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.

http://www.wikidata.org/entity/Q46924646

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Adenoviral vector-delivered pi ...... s of a phase I clinical trial.

@en

Adenoviral vector-delivered pi ...... s of a phase I clinical trial.

@nl

type

label

Adenoviral vector-delivered pi ...... s of a phase I clinical trial.

@en

Adenoviral vector-delivered pi ...... s of a phase I clinical trial.

@nl

prefLabel

Adenoviral vector-delivered pi ...... s of a phase I clinical trial.

@en

Adenoviral vector-delivered pi ...... s of a phase I clinical trial.

@nl

P1433

Q46924646-F15F6A1F-3022-4FCD-9E0C-9A05859919C5

P1476

Q46924646-AB4747C6-4E14-4EE9-8D6E-72D304C40F72

P2093

Q46924646-2274B414-4587-4ADC-B222-717CCF1810F8

Q46924646-22E5A0C2-BB9B-4F8A-ABD6-716304DF38AA

Q46924646-33B13D6D-8336-4600-8E18-AB668021C547

Q46924646-3495A269-15CC-4DC4-9024-2AF6502274F9

Q46924646-429CDBEA-494A-467B-81DE-070BB821003F

Q46924646-4FF0FDBB-F9D4-410A-B663-AE5661E889B3

Q46924646-699831F7-6D3E-41B1-8C03-7DE9B5D91E8D

Q46924646-A66F6F6A-BF1C-4832-9671-688363345931

Q46924646-BA91D98E-5670-4DAC-8657-123A74860649

Q46924646-E3C8D983-31FC-40E9-8DE9-5D2F32C55136

P304

Q46924646-0C75DA96-FB5E-42F5-93E5-3D9AA99D03AB

P31

Q46924646-0B3F5E14-5A95-4312-AC52-C2FB4B217329

P356

Q46924646-2AFEB682-A36E-4634-A9AE-E89491F31143

P433

Q46924646-79AA4412-B059-4240-92C4-75C56BBFDDCD

P478

Q46924646-2F795282-6809-49BD-B9EF-C828159B2A95

P577

Q46924646-87AD7BBB-AD3A-4746-8818-07B2E457B5D6

P5875

Q46924646-7989B4DF-2CB7-4DAD-9AD7-38ED074A9E45

P698

Q46924646-263AC300-04DB-43CD-8C6B-B15346B1ECC0

P921

Q46924646-AE3E163D-8986-4FCB-B62A-609AD5C74E43

Q46924646-FA2AEA25-5895-4593-8194-F9C9C6B5CA0E

P356

HUM.2006.17.167

P1433

Human Gene Therapy

P1476

Adenoviral vector-delivered pi ...... s of a phase I clinical trial.

@en

P2093

Anurag Gupta

http://www.w3.org/2001/XMLSchema#string

David A Saperstein

http://www.w3.org/2001/XMLSchema#string

Eric Holz

http://www.w3.org/2001/XMLSchema#string

J Timothy Stout

http://www.w3.org/2001/XMLSchema#string

Jennifer Macko

http://www.w3.org/2001/XMLSchema#string

Lisa L Wei

http://www.w3.org/2001/XMLSchema#string

Michael L Klein

http://www.w3.org/2001/XMLSchema#string

Peter A Campochiaro

http://www.w3.org/2001/XMLSchema#string

Quan Dong Nguyen

http://www.w3.org/2001/XMLSchema#string

Robert DiBartolomeo

http://www.w3.org/2001/XMLSchema#string

P304

167-176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2006.17.167

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7318851

http://www.w3.org/2001/XMLSchema#string

P698

16454650

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial